The home of the Audio Journal of Oncology
Geert Janssens MD

ARCON Improved Quality of Life in Advanced Laryngeal Cancer: Phase-III ARCON Trial

BARCELONA—Accelerated radiotherapy with carbogen and nicotinamide (ARCON) significantly improved regional control while maintaining excellent speech and swallowing for a majority of patients with advanced laryngeal cancer in a phase-III randomized trial comparing it with accelerated radiotherapy alone. Study author Geert Janssens MD, from Radboud University Medical Centre, presented the data at the 3rd ESTRO Forum (April 24-28, 2015) and gave Oncology Times reporter Sarah Maxwell the details.

Further reading

Sign up for news

* = required field